Aptinyx Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 43
Employees
  • Stock Symbol
  • APTX
Stock Symbol
  • Share Price
  • $4.20
  • (As of Wednesday Closing)

Aptinyx General Information

Description

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

Contact Information

Website
www.aptinyx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 909 Davis Street
  • Suite 600
  • Evanston, IL 60201
  • United States
+1 (847) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aptinyx Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.20 $4.33 $1.60 - $6.47 $266M 63.3M 1M -$1.26

Aptinyx Financials Summary

In Thousands,
USD 		TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 42,855 971 388,468
Revenue 2,482 3,669 6,574 4,962
EBITDA (51,943) (56,955) (52,824) (31,663)
Net Income (52,343) (57,410) (53,281) (32,068)
Total Assets 114,207 106,479 155,614 97,322
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aptinyx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.

Request a free trial

Aptinyx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.

Request a free trial

Aptinyx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
Drug Discovery
Evanston, IL
43 As of 2019
00000
00000000 00000

0000000

tation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
0000 000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

0000000

dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliq
0000000000000
Lexington, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aptinyx Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alector Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Lexington, MA 00 00000 000000000 00000
0000000 Venture Capital-Backed Framingham, MA 00 0000 0000000000 0000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 000.00 000000&0 000.00
000000000 Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
You’re viewing 5 of 13 competitors. Get the full list »

Aptinyx Executive Team (10)

Name Title Board Seat Contact Info
Norbert Riedel Ph.D Chief Executive Officer & Board Member
Andy Kidd President & Chief Operating Officer
Ashish Khanna Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Michael Martin Executive
Patricia Adams Senior Vice President, Human Resources and Administration
You’re viewing 5 of 10 executive team members. Get the full list »

Aptinyx Board Members (13)

Name Representing Role Since
Adam Koppel MD Bain Capital Board Member 000 0000
Henry Gosebruch Self Board Member 000 0000
James Topper Ph.D Frazier Healthcare Partners Board Member 000 0000
Norbert Riedel Ph.D Aptinyx Chief Executive Officer & Board Member 000 0000
Patrick Enright Longitude Capital Chairman & Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Aptinyx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial